Highest-materiality recent filing
Viatris Q2 2026: Revenue $3.8B (+5%), GAAP net loss $119M, raises full-year guidance
Total revenues $3.8B, up 5% reported and 3.5% operationally vs Q2 2025; GAAP net loss $119M.
Viatris issues €650M of 4.250% Senior Notes due 2033
Principal amount: €650,000,000 at 4.250% interest, maturing 2033.
Viatris Q1 revenues $3.5B (+8% YoY), adj. EBITDA $1.0B, reaffirms FY guidance
Total revenues $3.5B, up 8% reported and 3% operational vs Q1 2025.
Viatris CFO Theodora Mistras to depart; Paul Campbell appointed interim CFO
Chief Financial Officer Theodora Mistras voluntarily ceases role effective May 8, 2026, to pursue another professional opportunity.
Viatris Q4 2025 revenue $3.7B, FY $14.3B; announces restructuring with $700-850M charges
Q4 total revenues $3.7B, FY2025 total revenues $14.3B; met or exceeded all 2025 guidance metrics.
Viatris to sell Biocon Biologics stake for $815M in cash and equity from Biocon Limited
Viatris receives $400M cash and $415M in newly issued Biocon Ltd shares for Biocon Biologics convertible preferred equity.
Viatris Q3 results in line, raises FY guidance; acquires Aculys Pharma; NDA for estrogen patch
Total revenues for Q3 2025 in line with expectations; raising and narrowing 2025 guidance for revenues, adjusted EBITDA, adjusted EPS.
Viatris Q2 revenues beat expectations; reaffirms 2025 guidance, returns $630M+ to shareholders
Q2 total revenues exceeded company expectations; specific figures not disclosed.
Viatris reaffirms 2025 outlook after Q1 results; returns >$450M to shareholders YTD
Total revenues in Q1 2025 in line with expectations; three positive Phase 3 data readouts achieved.
FY2024 total revenues $14.7B; GAAP net loss $634M ($0.53 diluted loss); adjusted EPS $2.65.
Viatris shareholders reject say-on-pay proposal; approve 49M share increase for equity plan
Non-binding say-on-pay proposal failed with 49.23% in favor (458.9M against, 5.4M abstain).
Viatris Q3 2024: Revenue $3.8B, GAAP EPS $0.08, Adjusted EPS $0.75, Repaid $1.9B Debt
Total revenues $3.8B, operational revenue growth ~3% on divestiture-adjusted basis; new product revenues $133M.
Viatris launches cash tender offers for up to ~$1.8B in notes due 2025-2026
Any and all of $750M 1.650% Senior Notes due 2025 (Viatris) and €500M 2.125% Senior Notes due 2025 (Mylan) sought.
Viatris Q2: GAAP net loss $326M, adjusted EPS $0.69 up ~3%; raises new product revenue guidance
Total revenues $3.8B, operational growth ~2% on divestiture-adjusted basis; GAAP revenue declined ~3%
Viatris closes €1.95B divestiture of over-the-counter business to Cooper Consumer Health
Received €1.85B cash at closing (subject to adjustments) and up to €100M contingent additional consideration.
Viatris reports strong Q1: revenue $3.66B, adj. EPS $0.67, free cash flow $565M
Q1 revenue $3.66B, GAAP net earnings $113.9M; adjusted EBITDA $1.19B; GAAP EPS $0.09, adjusted EPS $0.67.
Viatris FY23 rev $15.4B, adj EBITDA $5.1B; 2024 guidance; $1B buyback boost; Idorsia deal
FY23 total revenues $15.4B, U.S. GAAP net earnings $54.7M, adjusted EBITDA $5.1B, free cash flow $2.4B.
Viatris signs definitive agreement to sell OTC business to Cooper Consumer Health
Viatris exercised put option on Jan 26, 2024; signed Transaction Agreement on Jan 29, 2024.
Viatris Chairman Coury transitions to Chairman Emeritus; Higgins elected new Board Chair
Robert J. Coury steps down as Executive Chairman, becomes Chairman Emeritus and Strategic Advisor; Melina Higgins elected as Board Chair.
Sanjeev Narula to step down as CFO on March 1, 2024; will receive severance of 2x base salary and target bonus.
Viatris Q3 2023: Revenue $3.94B, net earnings $332M, reaffirms FY adj. EBITDA and FCF guidance
Total revenues $3.94B; U.S. GAAP net earnings $332M; adjusted EBITDA $1.36B; free cash flow $738M.
Viatris President Rajiv Malik to Retire; President Anthony Mauro to Depart in Restructuring
Rajiv Malik, President, will retire as executive effective April 1, 2024, and remain on the Board and consult.
Viatris announces $6.94B in gross proceeds from remaining divestitures, achieving >12x multiple
Aggregated gross proceeds up to $6.94B from biosimilars, OTC, API, Women's Health, and non-core markets.
Viatris enters agreement to sell OTC business to Cooper Consumer Health for up to €1.95B
Up to €1.95B cash consideration: €1.85B at closing plus up to €100M contingent on return multiple.
Viatris reports strong Q2 2023: revenue $3.92B, net income $264M, reaffirms guidance
Total revenues $3.92B, U.S. GAAP net earnings $264M, adjusted EBITDA $1.31B, free cash flow $447M.
Viatris Q1 revenue $3.73B, net earnings $225M, adjusted EBITDA $1.34B; reaffirms full-year guidance
Total revenues $3.73B; US GAAP net earnings $225M; adjusted EBITDA $1.34B; free cash flow $923M.
Viatris appoints Scott A. Smith as CEO effective April 1, 2023; Michael Goettler departs
Scott A. Smith, former Celgene President/COO, appointed CEO effective April 1, 2023 to lead Phase 2 strategy.
Viatris reports FY2022 revenue $16.3B, meets adjusted guidance; provides 2023 outlook
FY2022 total revenues $16,263M; adjusted EBITDA $5,777M; free cash flow $2,547M.
Total consideration: $2B cash at close, $1B convertible preferred equity (12.9% stake), plus $335M in future cash payments in 2024.
Aggregate purchase price $700-750M cash; Oyster Point at $11/share upfront plus up to $2 CVR; expects Q1 2023 close.
Viatris Q3 revenue $4.08B, adj EBITDA $1.50B; reaffirms FY guidance; debt paydown ahead of schedule
Total revenues $4.08B; U.S. GAAP net earnings $354M; Adjusted EBITDA $1.50B.
Viatris Q2 2022: Revenue $4.12B, adj. EBITDA $1.48B, reaffirms guidance
Total revenues $4.12B; U.S. GAAP net earnings $314M; adjusted EBITDA $1.48B.
On May 4, 2026, the Board of Directors of the Company (the “Board”) appointed Paul Campbell, Viatris’ current Chief Accounting Officer and Corporate Controller, to also serve as interim Chief Financial Officer of the Company, effective May 8, 2026, until a permanent Chief Financial Officer is appointed by the Board.
On May 1, 2026, Theodora (“Doretta”) Mistras informed Viatris Inc. (the “Company”) that she would voluntarily cease to serve as Chief Financial Officer to pursue another professional opportunity.
Rajiv Malik and Harry Korman each notified the Company of his intention to not stand for re-election at the 2025 Annual Meeting and to retire as a member of the Board at the end of his current term
Rajiv Malik and Harry Korman each notified the Company of his intention to not stand for re-election at the 2025 Annual Meeting and to retire as a member of the Board at the end of his current term
On June 3, 2024, the Board of Directors (the “Board”) of Viatris Inc. (the “Company”) increased the number of directors on the Board from 11 to 12 and appointed Rogério Vivaldi Coelho, M.D., M.B.A. as an independent (as defined in the applicable NASDAQ listing rules) member of the Board with a term of office expiring at the Company’s 2024 annual meeting of shareholders and appointed him to the recently reestablished Science and Technology Committee of the Board, each appointment effective June 3, 2024.
On December 14, 2023, the Company appointed Theodora (Doretta) Mistras to serve as the Chief Financial Officer of the Company, effective as of March 1, 2024
On December 14, 2023, Viatris Inc. (the “Company”) determined that Sanjeev Narula, Chief Financial Officer, would transition from his role with the Company and cease to serve as Chief Financial Officer effective as of March 1, 2024.
Rajiv Malik, President, informed Viatris Inc. (the “Company”) of his intention to retire from his executive role with the Company effective as of April 1, 2024.
On October 20, 2023, the Company informed Anthony Mauro, President, Developed Markets, that he will depart from the Company effective as of April 1, 2024 as a result of an elimination of his position in connection with a realignment of the Company’s commercial function.
On May 19, 2023, the Board appointed Leo Groothuis as an independent (as defined in the applicable NASDAQ listing rules) member of the Board, effective immediately.
As a result of Mr. Coury’s agreement to serve in this advisory role, the independent members of the Board and Mr. Coury agreed that Mr. Coury will not stand for re-election at the 2023 Annual Meeting and will cease to be a director and to serve as an officer and employee of the Company effective as of the conclusion of the 2023 Annual Meeting.
Effective as of April 1, 2023, Michael Goettler, the Company’s current Chief Executive Officer, will cease to serve in that role and will cease to serve on the Board.
Max materiality 0.85 · Median 0.65 · Most common event earnings